Single-agent @entity1205 (Taxotere) has been shown to be highly active in metastatic @entity0 , with an overall response rate of 47%, median time to progression of 4 months, and survival of 10 months when administered as second-line therapy. These data compare favorably with those reported for @entity632 ( @entity632 ), which has been considered the most active single agent in this setting. This nonblinded, multicenter, randomized phase III study compared the median time to progression, response rate, quality of life, @entity137 , and survival after treatment with @entity1205 or @entity632 in @entity1 with metastatic @entity0 in whom previous alkylating chemotherapy failed. @entity1 were randomized to receive an intravenous infusion of either @entity1205 , 100 mg/m2, for 1 hour once every 3 weeks or @entity632 , 75 mg/m2, for 15 to 20 minutes once every 3 weeks. This preliminary analysis presents data on 200 of 326 @entity1 recruited. It was performed after the completion of @entity1 accrual. The median time to progression was greater in the @entity1205 group than in the @entity632 group (29 vs 21 weeks, respectively; P = not significant). Overall response rates were higher with @entity1205 (47% vs 27%), and fewer @entity1 in the @entity1205 group had progressive disease as their best overall response (10% vs 22%). Both regimens caused the same incidence and severity of @entity1398 , yet @entity1 treated with @entity632 had a higher incidence of @entity1398 . In addition, @entity632 produced a higher incidence of grade 3 to 4 @entity882 . @entity1370 led to discontinuation in 7 @entity1 and @entity204 in 2 @entity1 in the @entity632 group; fluid retention led to discontinuation in 1 @entity1 in the @entity1205 group. Based on this preliminary analysis, @entity1205 was more active and safer than @entity632 in @entity1 with metastatic @entity0 in whom previous alkylating chemotherapy failed.

XXXX vs @entity632 in metastatic @entity0 resistant to alkylating chemotherapy.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin', 'doxorubicin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'infection and febrile neutropenia'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['Cardiac toxicity'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity1205 :: (MESH:C067311,Chemical) :: ['Docetaxel']
